|drug3478||SMBI digital app Wiki||0.33|
|drug4748||standard newborn and infant care Wiki||0.33|
|drug4573||media package Wiki||0.33|
|D004066||Digestive System Diseases NIH||0.19|
|D005767||Gastrointestinal Diseases NIH||0.19|
|D044882||Glucose Metabolism Disorders NIH||0.19|
|D008659||Metabolic Diseases NIH||0.17|
|D008103||Liver Cirrhosis, NIH||0.17|
|D012120||Respiration Disorders NIH||0.15|
|D012140||Respiratory Tract Diseases NIH||0.13|
|D003920||Diabetes Mellitus, NIH||0.06|
|D018352||Coronavirus Infections NIH||0.02|
|D045169||Severe Acute Respiratory Syndrome NIH||0.01|
There are 9 clinical trials
To address the existing deficiencies in the knowledge regarding liver involvement and spectrum of clinical presentation and the impact of COVID-19 infection in patients of liver disease was planned. The present study will be a hospital based and the cases of confirmed COVID-19 infection will be evaluated in relation to liver involvement irrespective of pre-existing liver disease. The primary objective was to address the clinical presentation, biochemical alteration and outcomes of COVID-19 infection in subjects with chronic hepatitis, cirrhosis in comparison to those having infection in the absence of pre-existing liver disease
COVID19 pandemic currently represents a public health emergency. Based on current data, 15% of the affected individuals will develop a severe form of the disease requiring admission to hospital and respiratory support. Data show that age and cardiovascular pre-existing comorbidities predict a poorer outcome. Some evidence suggests that a subset of patients with poorer outcome present with a cytokine mediated inflammatory response and with a secondary HLH like clinical phenotype. No data are so far available with regard to the risk of severe COVID19 disease in the post stem cell transplantation setting. Recipients of allogeneic stem cell transplantation are by definition immunologically dysregulated and could potentially present with a unique immune-inflammatory response to COVID 19 infection. Moreover, the immunosuppression used to prevent/treat GVHD may also impact clinical progression and it is possible that because of their immunological defects, SCT patients could potentially have prolonged carriage of the virus and hence act as "super spreaders". The present study aims at documenting clinical and biological characteristics, including immunological profiling, of allogeneic stem cell transplant recipients presenting with severe COVID 19 infection and its impact on patients survival. This work may provide the scientific basis for targeted therapy with biological agents in this patient group.
This is a multi-centered, retrospective, observational study aimed at observing the current status of the management of gastrointestinal surgery during the COVID-19 pandemic, particularly the changes on surgery protocols and other key aspects of surgical workflow, so as to share experience with colleagues both domestic and abroad.
Description: proportion of patients presented with fever, proportion of patients refered to fever clinics, proportion of patients screened for COVID-19, method of screening (CT? nucleated acid test?)Measure: treatment of fevers at arrival Time: 1 day
Description: proportion of patients on whom fever occured, proportion of patients screened for COVID-19, method of screening (CT? nucleated acid test?)Measure: treatment of post-operative fevers Time: 1 day
Description: Duration of operation (≥180min/<180min); Intra-operative transfusion (Y/N); Surgical approach (Laparoscopy-involved/Open); Resection range (Non-radical/Radical); Lymph node dissection (Unknown/Not dissected/D1/D2 or above); Combined organ resection (Y/N); Post-operative complications (Y/N); Post-operative transfusion (Y/N); Post-operative hospital stay (≥7d/<7d)Measure: assorted surgical parameters Time: 1 day
Description: Out-patient of surgery (Open/Closed); Emergency of surgery (Open/Closed); Fever clinic (Open/Closed); Surgical ward (Open/Closed); Functional level of surgical ward (Receive emergency surgery patients only/Receive surgery patients only/Receive all kinds of patients); Isolation ward for suspected COVID-19 patients (With/Without); Bed number in each surgical ward room (1/2/≥3); Isolation area within surgical ward (With/Without); Usage of sub-pressure operation theaters (Routinely applied/Applied for suspected patients/Never applied); Protection level of surgeons in surgical ward (No specific protection/Regular medical masks/Any of N95 mask, eye/face shields, gowns); Protection level of surgeons in ER room (No specific protection/Regular medical masks/Any of N95 mask, eye shields, face shields, gowns)Measure: hospitals' protection measures and extent of implementation Time: 1 month
To investigate the difference of the difference between the nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the fatal Patients .The cross sectional study was undertaken to compare the clinical information (laboratory and radiologic characteristics)of nonfatal participants and fatal cases. The investigators wish figure out the clinical character of the fatal participants. The result may help the physician to find the fatal patients with COVID-19 more easily. The fatal patients with COVID-19 could be treated early.
Description: the counting of Lymphocyte(counts/L)Measure: Lymphocyte cell Time: 2 month
Description: d-dimer（mg/L）Measure: d-dimer Time: 2 month
Description: the counting of Platelets（(counts/L)）Measure: PLT Time: 2 month
Description: the level of C-reactive protein (mg/uL)Measure: CRP Time: 2 month
Description: lactate dehydrogenase ( U/L)Measure: LDH Time: 2 month
Description: creatine kinase (U/L)Measure: CK Time: 2 month
Description: prothrombin time(second)Measure: PT Time: 2 month
Description: alanine aminotransferase(U/L)Measure: ALT Time: 2 month
Description: aspartate aminotransferase(U/L)Measure: AST Time: 2 month
Description: natural killer cell(counts/L)Measure: NK cell Time: 2 month
Description: procalcitonin（ng/ml）Measure: PCT Time: 2 month
Description: interleukin-6(mg/L)Measure: IL-6 Time: 2 month
Description: CT scan featureMeasure: the clinical difference of radiologic characteristics between the fatal patients with COVID -19 and the non fatal cases Time: 2 months
Description: oxygen SaturationMeasure: SPO2 Time: 2 month
A new Coronavirus (SARS-CoV-2) emerged in Wuhan Province, China in December 2019 and rapidly spread around the world. To date, the data in the literature regarding the clinical and epidemiological characteristics of severe forms of CoVid-19 in patients with chronic respiratory disease are not well known. The hypothesis is that patients with chronic respiratory disease (COPD, asthma, bronchial dilatations, pulmonary hypertension, cystic fibrosis, obesity-hypoventilation syndrome, obstructive sleep apnea syndrome) infected with SARS-Cov-2 will have increased dyspnea and hypoxemia leading to hospitalization for severe forms more frequently than the general population. However, they do not appear to be more at risk of developing a critical form. This study is carried out in order to propose to estimate the prevalence of critical forms of CoVid19 among patients with chronic respiratory diseases hospitalized for severe forms.
Description: Value of 6 or greeter on WHO CoVid-19 scale, indicating of a critical form of CoVid-19.Measure: Percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale Time: up to 28 days (during hospitalisation)
Description: Radiological damage (extension of ground-glass) could be a predictive factor.Measure: Determined potential predictive factors of critic form in patients with chronic lung diseases Time: up to 28 days (during hospitalisation)
Description: intra-hospital death, intra-ICU deathMeasure: Determined percentage of death Time: up to 28 days (during hospitalisation)
Description: in days (or duration at a different flow rate compared to long-term home oxygen therapy prior to hospitalization)Measure: Determined duration of oxygen therapy Time: up to 28 days (during hospitalisation)
Description: in days for patients with chronic respiratory disease between the date of admission and the date of discharge. Patients who died during hospitalization will be assigned the highest cohort value.Measure: Determined duration of hospitalization Time: up to 28 days (during hospitalisation)
Description: values will be measured at D3, D7 and D14 in each of the groups. Patients who do not reach D7 and D14 will have the last postponementMeasure: Determine mean values of the WHO CoVid-19 infection progression scale measured Time: up to 28 days (during hospitalisation)
This study aim is to assess impact of COVID-19 infection during pregnancy on outcome of pregnancy, and on developement of the child in early life.
Description: Incidence of miscarriage, premature delivery, low birth weight, preeclampsia, chorioamnionitisMeasure: Outcome of pregnancy Time: Up to the delivery
Description: Measure of antibodies in maternal serum at deliveryMeasure: Prevalence of positive serology to SARS-CoV-2 at delivery Time: At the delivery
Description: Measure the ratio of cord blood antibodies on maternal antibodies titersMeasure: Transplacental transfer of antibodies to SARS-CoV-2 Time: At the delivery
Description: Placental histology will be performed in women tested positive for SARS-CoV-2 during pregnancyMeasure: To characterize placental alterations related to SARS-CoV-2 infection Time: At the delivery
Description: Measure of antibodies in cord blood and at the age of 1 monthMeasure: To characterize the immunity transmitted to the newborn to cord blood and its persistence at the age of 1 month of life Time: Up to 1 month post delivery
Description: Occurence of infectious disease, neurological development, growthMeasure: Clinical evolution of the children Time: Up to 3 years
The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the COVID-19 (Coronavirus Disease-2019) in December 2019 has led to an unprecedented international health situation. Exceptional measures have been taken by public authorities worldwide in order to slow the spread of the virus and prevent healthcare systems from becoming overloaded. In France, a national lockdown has been established during approximately 2 months to increase social distancing and restrict population movements. Hospital routine care appointments have been cancelled, in order to reallocate medical resources towards COVID-19 units and limit contacts between patients within hospitals or waiting rooms. While the virus itself, the disease and potential treatments are currently extensively studied, little data are available on the effect of these public health decisions on the management of a chronic condition such as diabetes. The French regional CONFI-DIAB study aims at assessing the collateral impact of routine care cancellation during the national lockdown due to COVID-19 in patients with a chronic condition such as diabetes. Special attention will be given to metabolic control and access to health care. This cross-sectional study should provide information on the consequences of a global lockdown and the associated routine care cancellation on the management of diabetes, and inform future decision making in the event of a new pandemic.
Description: HbA1c levels before and after the lockdown period. A 3 months period is required between the 2 values.Measure: Compare glycated hemoglobin levels of patients with diabetes from the University Hospital of Nancy between the period preceding and following the lockdown related to the COVID-19 pandemic. Time: 6 months period prior to lockdown - 6 weeks period following the end of the lockdown
Description: Use type of diabetes, BMI, lipid profile, micro- and macro-comorbidities and usual therapies from medical recordsMeasure: Describe the clinical and biological characteristics of patients with diabetes followed in routine care at the University Hospital of Nancy Time: 6 weeks period following the end of the lockdown
Description: Use BMI, lipid profile, renal and hepatic function from medical recordsMeasure: Describe the change from baseline of biological and clinical parameters of patients with diabetes followed in routine care at the University Hospital of Nancy between the period preceding and following the lockdown. Time: 6 months period prior to lockdown - 6 weeks period following the end of the lockdown
Description: Ketosis, Ketoacidosis, severe hypoglycemia, COVID-19 infection, hospitalizationMeasure: Describe the proportion of patients who presented with one or more significant clinical event during the lockdown. Time: 6 weeks period following the end of the lockdown
Description: Proportion of patients who forgot and/or discontinued one or several medication(s), medication involved, duration and frequency of omission/discontinuationMeasure: Describe the proportion of patients who forgot and/or discontinued one or several medication(s) during the lockdown. Time: 6 weeks period following the end of the lockdown
Description: Porportion of patients who modified their usual level of physical activity and/or their consumption of alcohol and/or tobaccoMeasure: Describe the proportion of patients who changed their lifestyle's habits during the lockdown. Time: 6 weeks period following the end of the lockdown
Description: Proportion of patients who consulted their GP, a specialist physician, pharmacist, biologist, nurse, paramedic, other healthcare professional; type of visit (regular face to face, telemedecine); method for prescription renewal; reason for delay in care; hospitalization (excluding for COVID-19)Measure: Describe healthcare consumption of patients with diabetes during the lockdown. Time: 6 weeks period following the end of the lockdown
Description: Proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19.Measure: Describe the proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19. Time: 6 weeks period following the end of the lockdown
Our hypothesis: Serum Vitamin D (25(OH)D) is significantly lower in severe versus non-severe COVID-19 infections and that this is a function of ethnicity. There is an association between vitamin D status and various cytokines (pro-inflammatory molecules). The primary objective of this research is to provide a snap shot of vitamin D status in patients from the South-East London area by age, sex, ethnicity and BMI and demonstrate ethnic differences in vitamin D status as well as its associations with severe vs non-severe COVID-19 infections. The secondary objective is to determine if there is an association between vitamin D status and various cytokines (pro-inflammatory molecules) and severity of disease.
Description: All vitamin D results performed by the Nutristasis Unit at St. Thomas' since January 2020 (N= ~15000) together with age, weight and height if available, ethnicity and other relevant laboratory markers (Ca, adjusted calcium, PTH, Mg, phosphate, liver and renal profile, Covid-19 screening, CRP, Haematinics, FBC) if they were tested within two weeks of the sample being measured for vitamin D will be acquired. The results of this audit will provide us with a snap shot of vitamin D status in patients from the South-East London area by age, sex, ethnicity and BMI (weight in kg/height2). Correlation analysis will also be undertaken with other laboratory parameters.Measure: Collecting vitamin D results in patients from the South-East London area together with age, sex, ethnicity and BMI and other relevant laboratory results. Time: January-June 2020
Description: All Covid-19 screening results together with vitamin D (nmol/L), ethnicity, age (yrs), weight (m) and height to obtain BMI, length of stay in hospital including ICU in days (if applicable), type of illness, recovered or not (y or no), associated health conditions, CRP, Ferritin, Haematinics, vitamin A and E, procalcitonin, LDH, INR, fibrinogen, FBC, D-dimers, CK, Troponin-T, cytokines, renal function and electrolytes will be collected from patients tested at GSTT NHS Trust. We expect that only a small number of patients who had Covid-19 screening performed would have had vitamin D, cytokines and other markers measured. However, we estimate that we will be able to identify a sufficient number of Covid-19 patients for regression and correlation analysis from this data.Measure: Collecting Covid-19 screening results together with age, sex, ethnicity and BMI and other relevant laboratory results. Time: March-June 2020
One of the major problems in suppressing the spreading of an epidemic resides in understanding and monitoring its propagation patterns, and in evaluating how these are modified by enforced policies. The standard solution requires detailed information at the microscopic scales, e.g. how infected people have moved and whom they came in contact with, which is hardly ever available. The researchers propose a novel approach to the study of the propagation of COVID-19, in which a proxy of this information is derived at macroscopic scales. This will be based on two ingredients: the spatiotemporal study in shiny with mathematical models with aggregated or non aggregated data and the reconstruction of functional networks of spreading patterns, and the development of a supporting software.
Description: spatiotemporal spread of COVID-19 patient in our hospitalMeasure: spatiotemporal spread Time: February 1, 2020 to September 30, 2020
Description: risk classification score of each patients with clinical and analytical variablesMeasure: classification score Time: February 1, 2020 to September 30, 2020
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports